Skip to main content

and
  1. Article

    Open Access

    Hairy cell leukemia variant and WHO classification correspondence Re: 5th edition WHO classification haematolymphoid tumors: lymphoid neoplasms

    Michael Grever, Leslie Andritsos, Mirela Anghelina, Evgeny Arons in Leukemia (2024)

  2. No Access

    Article

    Comparison of karyotype scoring guidelines for evaluating karyotype complexity in chronic lymphocytic leukemia

    Matthew R. Avenarius, Ying Huang, Adam S. Kittai, Seema A. Bhat in Leukemia (2024)

  3. Article

    Correction: Evaluation of bleeding events in patients receiving acalabrutinib therapy

    Pooja S. Kumar, Tracy Wiczer, Lindsay Rosen, Arthur J. Pollauf, Amy Zheng in Leukemia (2023)

  4. No Access

    Article

    Evaluation of bleeding events in patients receiving acalabrutinib therapy

    Pooja S. Kumar, Tracy Wiczer, Lindsay Rosen, Arthur J. Pollauf, Amy Zheng in Leukemia (2023)

  5. No Access

    Article

    Depth of response and progression-free survival in chronic lymphocytic leukemia patients treated with ibrutinib

    Audrey M. Sigmund, Ying Huang, Amy S. Ruppert, Kami Maddocks, Kerry A. Rogers in Leukemia (2022)

  6. No Access

    Article

    Second cancer incidence in CLL patients receiving BTK inhibitors

    Chronic lymphocytic leukemia (CLL) is associated with perturbed immune function and increased risk for second primary malignancies (SPM). Ibrutinib and acalabrutinib (BTKi) are effective therapies for CLL resu...

    David A. Bond, Ying Huang, James L. Fisher, Amy S. Ruppert, Dwight H. Owen in Leukemia (2020)

  7. No Access

    Article

    Incidence of opportunistic infections during ibrutinib treatment for B-cell malignancies

    Kerry A. Rogers, Luay Mousa, Qiuhong Zhao, Seema A. Bhat, John C. Byrd in Leukemia (2019)